Breckenridge's Milnacipran Hydrochloride ANDA205071 Receives AP Status
The FDA has granted an Abbreviated New Drug Application (ANDA) approval status to Breckenridge for Milnacipran Hydrochloride.
Asset / Drug
Drug and asset intelligence for Breckenridge with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.